Sanara Medtech INC 8-K filings

Sanara MedTech announced a 9% revenue increase for Q2 2026 to $28.1 million, alongside a pending acquisition by MiMedx.

Sanara MedTech Inc. announces an Agreement and Plan of Merger with MiMedx Group, Inc., detailing terms for acquisition and shareholder consideration.

MiMedx Group, Inc. announced its definitive agreement to acquire Sanara MedTech Inc. in a cash and stock transaction valued at approximately $350 million.

Sanara MedTech Inc. has mutually terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective immediately, as it shifts strategic focus.

Sanara MedTech reported 19% year-over-year revenue growth to $27.8 million and achieved GAAP net profitability for the first quarter of 2026.

Sanara MedTech Inc. announced robust fourth quarter and full year 2025 financial results, with net revenue exceeding $100 million, and reaffirmed its 2026 financial guidance.

Sanara MedTech Inc. announced preliminary Q4 and full-year 2025 financial results with significant revenue growth and introduced optimistic 2026 guidance.

Sanara MedTech Inc. will present its 2026 fiscal year priorities and strategy at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025.

Sanara MedTech Inc. announced its third quarter 2025 financial results, reporting a 22% year-over-year net revenue increase driven by its core surgical business, alongside a significant net loss due to discontinued operations.

Sanara MedTech Inc. announced a strategic realignment, discontinuing its Tissue Health Plus operations to concentrate resources on its core surgical business.

Sanara MedTech Inc. announced the appointment of Seth D. Yon as President and Chief Executive Officer, effective September 15, 2025, succeeding Ronald T. Nixon who will remain Executive Chairman.

Sanara MedTech Inc. reported a 28% year-over-year net revenue increase in Q2 2025, reaching $25.8 million, while also announcing a formal process to evaluate strategic alternatives for its Tissue Health Plus (THP) subsidiary.

Sanara MedTech Inc. announced that all proposals, including the re-election of its eight directors and the ratification of its independent accounting firm, were approved by shareholders at its Annual Meeting held on May 22, 2025.

Sanara MedTech Inc. announced the retirement of Michael D. McNeil, its Chief Accounting Officer and Chief Administrative Officer, effective August 19, 2025, with CFO Elizabeth B. Taylor assuming his principal accounting officer duties.

Sanara MedTech Inc. announced a 26% increase in net revenue for the first quarter of 2025, driven by strong performance in soft tissue repair products, but reported a net loss of $3.5 million.

Sanara MedTech Inc. is furnishing an investor presentation in connection with its upcoming presentation at the Planet MicroCap Showcase: VEGAS 2025.

Sanara MedTech Inc. has acquired CarePICS, a virtual platform for vascular and wound care, for an initial consideration of $2.0 million plus potential earnout payments.

Sanara MedTech Inc. announced a 49% increase in Q4 net revenue and a 33% increase in full-year net revenue for 2024, driven by strong performance in its Sanara Surgical segment.

Sanara MedTech Inc. has appointed Elizabeth Taylor as its new Chief Financial Officer, succeeding Michael McNeil, who will now serve as Chief Accounting Officer and Chief Administrative Officer.

Sanara MedTech secures exclusive U.S. rights to OsStic bone void filler and related technologies from Biomimetic Innovations, accompanied by a minority equity investment.

Sanara MedTech anticipates a significant year-over-year revenue increase of 45% to 48% for the fourth quarter and 32% to 33% for the full year 2024.

Sanara MedTech Inc. has released an investor presentation in connection with its participation in the Piper Sandler 36th Annual Healthcare Conference.

Sanara MedTech Inc. achieved its twelfth consecutive record net revenue quarter, with a 35% year-over-year increase, but also reported a larger net loss due to increased operating expenses.

Sanara MedTech Inc. has appointed Keith Myers to its Board of Directors, following the resignation of James W. Stuckert, effective October 4, 2024.

Sanara MedTech Inc. has formalized an employment agreement with CEO Ronald T. Nixon, outlining his compensation and terms of service.

Sanara MedTech has made a minority investment in ChemoMouthpiece and secured an exclusive U.S. distribution agreement for its oral cryotherapy device through a joint venture with InfuSystem.

Sanara MedTech announced record second-quarter revenue of $20.2 million, marking its eleventh consecutive quarter of revenue growth, and secured a $55 million non-dilutive term loan to support future growth.

Sanara MedTech Inc. has furnished an investor presentation to be used in meetings with investors and analysts, including a webcast on June 20, 2024.

Sanara MedTech Inc.'s shareholders approved the 2024 Omnibus Long-Term Incentive Plan at the 2024 Annual Meeting, effective June 12, 2024.

Sanara MedTech Inc. held its 2024 Annual Meeting, approving an amended certificate of formation and electing eight directors.